Page 8 - Malaria Programme News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Perennial malaria chemoprevention (PMC) is newly formulated strategy endorsed in June 2022 by the World Health Organization and builds off the previously recommended but poorly implemented strategy of intermittent preventive treatment of malaria in infants – IPTi. IPTi – the provision of single dose Sulphadoxine Pyrimethamine (SP) delivered through the Expanded Program of Immunization (EPI) at times of childhood immunisation at approximately 3, 4 and 9 months of age was shown to provide infants with protection against malaria, anaemia and all cause hospital admissions.

​The LSHTM-Charité Global Health Lecture Series brings together leading scientists from the UK, Germany and further afield to present cutting-edge research on pressing global health issues and to discuss the implications of their work for policy and practice. The series is supported by the Bill and Melinda Gates Foundation.

The Annopheles stephensi mosquito species, considered to be an Asian and Arabian Peninsula malaria vector, has spread to at least five African countries in the past decade, according to the World Health Organisation.

A new World Health Organization (WHO) initiative has been launched that aims to stop the further spread of this invasive mosquito species in the region. The WHO had identified the spread of Anopheles stephensi as a significant threat to malaria control and elimination in 2019 - particularly in Africa, where the disease hits hardest. Originally native to parts of South Asia and the Arabian Peninsu

Impact of the SMC on malaria morbidity, parasite resistance to antimalarial drugs, molecular and the immunity affecting the incidence of malaria in children